Preliminary study assesses durability of NAb titers against Omicron after mRNA-1273 booster
Researchers from Moderna, the developers of one key vaccine, have been investigating its ability to protect against the Omicron variant.
Stay updated with breaking news from Serum Neutralizing Activity. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers from Moderna, the developers of one key vaccine, have been investigating its ability to protect against the Omicron variant.
Moderna's COVID vaccine effective against emerging variants including Delta Researchers in the United States have analyzed the neutralizing activity of Moderna’s mRNA-1273 vaccine against several variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19). “The emergence of SARS-CoV-2 variants has led to growing concerns over increased transmissibility and the ability of some variants to partially escape immunity,” writes the team from Moderna Inc. in Cambridge, Massachusetts. Now, the researchers have compared t...